A Profile of the Pharmaceutical Manufacturing Industry: Russia

Add bookmark

We respect your privacy, by clicking "Download Your Copy" you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. You have the right to object. In addition, you will receive our e-newsletter, including information on related online learning opportunities. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here.

The issues of increasing manufacturing capacity and improving processes have became a top priority for key industry players in the Russian Pharma market.

Under the "Pharma 2020" strategy, the government intends to help existing local pharmaceutical companies finance R&D in order to increase production of innovative pharmaceuticals and to encourage the development of new local companies.

The most significant objective of the plan is to have local manufacturers producing 50% of the drugs available by 2020, of which 80% will be innovative drugs. Many international players are looking to set up their own manufacturing facilities or contract manufacture in the region in order not to miss out exciting opportunities this market has to offer.

In conjunction with IQPC’s Pharmaceutical Manufacturing Forum Russia & CIS, taking place on 18-20 September 2012 in Moscow, Russia, Pharma IQ examines local and international stakeholders in the Russian pharmaceutical market and their market share.


Have Your Say
Rate this feature and give us your feedback in the comments section below